Provided by Tiger Fintech (Singapore) Pte. Ltd.

RAPT Therapeutics, Inc.

10.49
-0.3100-2.87%
Post-market: 10.490.00000.00%19:04 EDT
Volume:31.80K
Turnover:334.68K
Market Cap:173.46M
PE:-0.96
High:10.98
Open:10.57
Low:10.10
Close:10.80
Loading ...

RAPT Therapeutics Shares Rise After JPMorgan Upgrade

MT Newswires Live
·
31 Jul

JPMorgan Upgrades RAPT Therapeutics to Neutral From Underweight, Price Target is $14

MT Newswires Live
·
30 Jul

RAPT Therapeutics (RAPT) was upgraded to a Hold Rating at J.P. Morgan

TIPRANKS
·
30 Jul

U.S. RESEARCH ROUNDUP-Penumbra, UnitedHealth, Visa

Reuters
·
30 Jul

RAPT Therapeutics trading halted, volatility trading pause

TIPRANKS
·
15 Jul

Rapt Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Ashley L. Dombkowski

Reuters
·
01 Jul

RAPT Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Scott Braunstein

Reuters
·
25 Jun

Rapt Therapeutics appoints Scott Braunstein, Ashley Dombkowski to board

TIPRANKS
·
24 Jun

Press Release: RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Dow Jones
·
23 Jun

Rapt Therapeutics Announces 1-for-8 Reverse Stock Split Effective June 16, 2025

Reuters
·
18 Jun

RAPT Therapeutics trading halted, news pending

TIPRANKS
·
17 Jun

RAPT Therapeutics Announces 1-for-8 Reverse Stock Split Effective June 16, 2025

Reuters
·
13 Jun

RAPT Therapeutics Announces Development Plans for RPT904

TIPRANKS
·
10 Jun

Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity

TIPRANKS
·
06 Jun

Rapt Therapeutics to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Reuters
·
05 Jun

Rapt Therapeutics Inc. Announces Approval of 2025 Equity Incentive Plan and Amended Employee Stock Purchase Plan

Reuters
·
30 May

RAPT Therapeutics Faces Nasdaq Delisting Notice

TIPRANKS
·
29 May

Rapt Therapeutics Inc. Announces Nasdaq Listing Rule Deficiency

Reuters
·
29 May

UBS Adjusts Price Target on RAPT Therapeutics to $1 From $2, Maintains Neutral Rating

MT Newswires Live
·
22 May

Rapt Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
22 May